Integrative Hormone Health and Evidence-Based Care: An Educational Guide by Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

Abstract

In this educational post, I explain how I evaluate and manage complex hormone-related concerns using an integrative, evidence-based approach that includes chiropractic-informed neuromusculoskeletal assessment, functional nutrition, and precision medicine. I cover iron physiology and anemia patterns; intrauterine device (IUD) pharmacology and clot risk; localized versus systemic hormone effects; individualized progesterone strategies (including sublingual versus oral delivery); cortisol testing (salivary and serum) and clinical interpretation; male fertility, testosterone recovery, and selective estrogen receptor modulation timing; endocrine considerations after ductal carcinoma in situ (DCIS) and the rationale for risk-stratified shared decision-making; creatinine, inflammation, and differential diagnosis; hormones after transient ischemic attack (TIA) and migraine biology; immediate-release vs extended-release medications; endometriosis and menopause care; thyroid optimization (T4/T3, reverse T3, desiccated thyroid) and gut-thyroid interactions; estriol/estradiol use; and practical treatment pearls. Along the way, I highlight how integrative chiropractic care complements endocrine management—by modulating autonomic tone, improving sleep, reducing pain and inflammation, and enhancing gastrointestinal and musculoskeletal function.

Understanding Identity in Health: The Person Behind the Lab Values

When patients sit with me, I remember that each person carries multiple identities—parent, professional, athlete, caregiver—each of which affects health behaviors and resilience. Therapeutic success begins when we align care with those identities. In practice, this means:

• Clarifying the patient’s values and goals before choosing labs or therapies
• Matching treatment intensity to life demands and recovery capacity
• Addressing behavioral barriers compassionately and concretely

This person-centered lens is crucial when interpreting hormone and metabolic data; identical lab values can represent very different clinical realities depending on the person’s stress load, sleep, nutrition, and physical function. In integrative chiropractic care, this extends to structured movement progressions, spinal and peripheral joint assessments, and autonomic balancing techniques that lower sympathetic overdrive—improving sleep quality, pain thresholds, and endocrine harmony (Thayer & Lane, 2009).

Iron Physiology, Ferritin, and Why Symptoms Matter

Iron biology is not one number. Total body iron, serum iron, transferrin saturation, ferritin, and reticulocyte indices must be integrated with symptoms and root-cause assessment.

• Ferritin reflects iron storage and is also an acute-phase reactant—rising with inflammation (Camaschella, 2015).
• Serum iron fluctuates diurnally and with meals; it should not be the sole determinant.
• Transferrin saturation (TSAT) and soluble transferrin receptor can help differentiate iron deficiency from anemia of inflammation.

When ferritin is below approximately 30 ng/mL with fatigue, hair shedding, restless legs, or exercise intolerance, I investigate the “why” before reflexively supplementing:

• Blood loss: gastrointestinal sources, heavy menses, postpartum losses
• Absorptive issues: celiac spectrum, H. pylori, hypochlorhydria, SIBO, inflammatory bowel disease
• Increased demands: pregnancy, endurance training
• Hemolysis or chronic inflammation

In neonates, the early postnatal transition “pink hour” involves fluid shifts and physiologic changes; clinical vigilance for anemia or hypoxia is warranted, but iron decisions must be individualized and evidence-based.

Why integrative chiropractic care helps: Gentle thoracic mobility, diaphragmatic breathing coaching, and rib mechanics can improve ventilation, autonomic balance, and exercise tolerance, which, paired with iron repletion and anti-inflammatory nutrition, accelerates symptom recovery. In my clinic, I often layer ferritin targets (50–100 ng/mL for symptomatic individuals) with gut-healing protocols and gradual reconditioning to prevent relapse (Camaschella, 2015).

IUD Pharmacology: Progestin Families, Clot Risk, and Local Versus Systemic Effects

Not all progestins are the same. Progestins derive from different families (estrane, gonane, and pregnane) with distinct receptor affinities and thrombotic profiles (Dragoman & Gaffield, 2016).

• Levonorgestrel (e.g., Mirena, Liletta) is a gonane with potent local endometrial effects; systemic levels are low.
• Norethindrone is an estrane with different androgenic and metabolic profiles.
• Depot medroxyprogesterone acetate (DMPA) is a pregnane with systemic impact and differing effects on lipids and bone.

Key concept: The levonorgestrel IUD’s primary action is local—thickening cervical mucus, attenuating endometrial proliferation, and modulating the local immune milieu—leading to a lower systemic risk of clotting compared to combined estrogen-progestin methods (Curtis et al., 2016). Patients often read online that “every IUD is the same,” or see references to novel shapes and “hexagon designs.” The reality is that the vast majority of contemporary IUDs follow well-characterized forms and release profiles with robust safety data.

Clinical reasoning:

• For patients with migraine with aura or thrombotic risk, a levonorgestrel IUD offers effective contraception with minimal systemic estrogen exposure (Curtis et al., 2016).
• For heavy bleeding, levonorgestrel IUDs reduce menstrual blood loss and improve iron stores—an elegant way to address iron deficiency at the source.

Integrative chiropractic fit: Pelvic floor–aware care and lumbopelvic mechanics matter. Optimizing sacroiliac and lumbar function can reduce pelvic pain and dyspareunia while patients adapt to an IUD, improving adherence to a therapy that, in many cases, meaningfully reduces anemia risk.

Progesterone: Tolerability, Dosing, and Why Sublingual Can Help

Many patients report mood lability or sedation with oral micronized progesterone. The clinical art involves matching the route and dose to the patient’s physiology.

• Oral micronized progesterone (OMP) 100–200 mg at night leverages first-pass metabolism to allopregnanolone, enhancing GABAergic tone and sleep.
• For patients sensitive to OMP, sublingual delivery can reduce hepatic first pass and alter neurosteroid profiles. Clinically, approximately 100 mg sublingual often parallels 200 mg oral in terms of effect due to reduced first-pass metabolism, though bioavailability varies (Prior & Hitchcock, 2012).
• Compounded troches can be portioned (e.g., 200 mg troche cut to quarters) to fine-tune dosing.

Why this approach works: Progesterone modulates GABA-A receptor activity through neuroactive metabolites such as allopregnanolone, producing anxiolytic and sleep-promoting effects. Reducing first-pass conversion can adjust the balance between calming and sedating effects, improving tolerability for patients who feel “foggy” or “flat” on standard oral doses.

PCOS and androgen balance: In hyperandrogenic states, cyclical or continuous progesterone can mitigate estrogen-dominant endometrial risk while avoiding exacerbation of mood symptoms. I often pair this intervention with insulin-sensitizing nutrition, resistance training, sleep timing, and gut-directed therapies; this multidomain approach rebalances the HPO axis from the bottom up (Teede et al., 2018). Chiropractic-informed coaching on circadian rhythm and stress modulation enhances outcomes by normalizing autonomic inputs that modulate GnRH pulsatility.

Cortisol Testing Strategy: Salivary Curves and Practical Serum Use

Cortisol is a rhythm, not a spot number.

• A 4–5-point salivary cortisol curve captures diurnal variation: high on waking, a gradual decline, and a nadir at night (Stalder et al., 2016).
• Morning serum cortisol is helpful for adrenal sufficiency screening or when salivary testing is not feasible.
• Pairing fasting insulin and glucose with cortisol provides a clearer picture of HPA-metabolic crosstalk.

Why we care: Flattened or shifted cortisol curves drive sleep fragmentation, central adiposity, and thyroid conversion issues. In integrative care, we can restore rhythm through targeted morning light exposure, consistent feeding windows, breathwork, and graded exercise—interventions that complement spinal manipulation to support autonomic recalibration. Multiple studies demonstrate that manual therapies can influence vagal tone and pain processing, indirectly improving cortisol dynamics (Martínez-De La Cal et al., 2023).

Male Fertility, Testosterone, and Short-Term SERMs: Timing Is Everything

In males desiring fertility, exogenous testosterone suppresses GnRH, LH, and FSH, lowering intratesticular testosterone and sperm production. Short-term use of selective estrogen receptor modulators (SERMs) such as clomiphene citrate can increase LH/FSH levels, thereby boosting endogenous testosterone and spermatogenesis (Patel et al., 2019).

• I consider clomiphene for 3–6 months in men in their 20s–30s with low T and near-term fertility goals.
• It is not for indefinite use; prolonged estrogen receptor blockade is neither physiologic nor risk-free.
• Cycling off peptides or exogenous androgens may be paired with SERM “bridge” and lifestyle optimization (sleep, resistance training, micronutrient adequacy: zinc, vitamin D, omega-3s).

Why lifestyle first helps younger men: Adaptive capacity is high. Sleep extension, body composition changes, and improvements in insulin sensitivity can raise total testosterone from the 300s to the 700–800s over 6–9 months in many patients, reducing the need for pharmacotherapy (Kelly & Jones, 2013). I use microbiome-directed nutrition to lower gut-derived metabolites, such as TMAO and endotoxin, that impair Leydig cell function and vascular health; my clinical observations align with growing evidence that metabolic inflammation suppresses the HPG axis. Chiropractic’s role is pragmatic: pain relief and improved movement fidelity reduce allostatic load, enabling higher training quality and better endocrine outcomes.

Breast Pathology, Receptor Status, and Individualized Hormone Decisions

Terminology matters. Ductal carcinoma in situ (DCIS) is a non-invasive neoplastic process classified as stage 0; its management varies widely across systems. Receptor positivity (estrogen, progesterone, androgen) does not automatically equate to a systemic hormone contraindication in every scenario. The right approach is nuanced, patient-centered, and risk-stratified.

• After bilateral mastectomy with no residual breast tissue, systemic estrogen risk profile fundamentally differs from a recent lumpectomy with adjuvant therapy.
• Shared decision-making requires transparent discussion of benefits (cardiometabolic, skeletal, vasomotor, cognitive) and risks, with oncologic input and documentation.

Evidence update: Contemporary analyses suggest that physiological transdermal estradiol with adequate progesterone does not increase breast cancer risk in average-risk women to the extent previously assumed, especially when started near menopause (The 2022 Hormone Therapy Position Statement of The North American Menopause Society, 2022). However, survivors of hormone-receptor–positive disease fall into a separate category; standard oncologic guidance generally avoids systemic estrogen, yet some case-by-case exceptions exist under specialist care.

Clinical observation: I have supported patients many years out from treatment who opted, after detailed counseling and signed informed consent, to address debilitating symptoms with carefully selected modalities (e.g., vaginal estriol for GSM, nonhormonal agents for vasomotor symptoms, sleep protocols). The guiding principle is respect for patient autonomy and rigorous risk communication.

Integrative chiropractic role: Addressing sleep, pain, and pelvic floor dysfunction can substantially reduce symptom burden even when systemic estrogen is deferred. This often allows women to regain function without escalating pharmacotherapy.

Creatinine, Inflammation, and When “High” Isn’t Pathologic

Isolated high serum creatinine with normal cystatin C, bland urinalysis, and stable eGFR may reflect higher muscle mass or recent intense training rather than kidney disease. Chronic low-grade inflammation can elevate ferritin and alter creatinine-eGFR interpretations. My approach:

• Recheck with standardized hydration and activity conditions
• Add cystatin C and urinary albumin-to-creatinine ratio
• Evaluate CRP, ESR, and metabolic markers
• Consider body composition (DXA or BIA)

In men, modestly higher creatinine is common at baseline. Markedly high or rising values mandate renal workup. Clinically, I frequently see inflammation-driven “false flags” resolve with gut-focused anti-inflammatory nutrition, sleep normalization, and graded training—supported by spinal and rib mechanics work that improves ventilatory efficiency and training tolerance.

Hormones After TIA and Migraine: Myth, Mechanism, and Safer Paths

Legacy neurology teaching often equated “estrogen” with stroke risk without distinguishing between oral ethinyl estradiol in contraceptives versus transdermal physiological estradiol in menopause therapy. Current evidence:

• Oral estrogen increases hepatic first-pass effects, raising clotting factors and stroke risk; transdermal estradiol at physiologic doses appears safer in many populations (Vinogradova et al., 2019).
• For migraine with aura, non-estrogen options or ultra-low-dose non-oral regimens are favored (MacGregor, 2018).

Integrative strategy after TIA:

• Prioritize vascular risk reduction: blood pressure control, lipid optimization, insulin sensitivity, sleep apnea screening, an anti-inflammatory diet, and exercise.
• If hormone therapy is considered, choose the lowest effective non-oral estradiol with endometrial protection and ongoing risk review, in collaboration with neurology and cardiology.
• Chiropractic-informed care that normalizes cervicogenic contributors to headache and reduces sympathetic arousal can decrease migraine frequency and intensity, complementing medical therapy.

Immediate-Release vs Extended-Release Medications: When Peaks Are Helpful

I often favor immediate-release formulations when clinical objectives include robust nocturnal effects (e.g., sleep with progesterone) or minimizing long tail sedation. With thyroid and adrenal-adjacent agents, split dosing can mirror physiology and reduce side effects.

Why this works:

• Immediate-release creates predictable peaks aligned with symptom windows.
• Extended-release can flatten therapeutic impact and, for some agents, worsen adverse effects by blunting physiologic feedback.
• Patient-reported outcomes guide the final choice.

Endometriosis, Menopause, and Why Progesterone Still Matters

For postmenopausal patients with a history of endometriosis, even after hysterectomy, residual implants can remain hormonally responsive. Guidance from gynecologic societies recommends adding progesterone when systemic estrogen is used, regardless of uterine status, to mitigate ectopic endometrial stimulation (ACOG, 2010; Gemmell et al., 2017).

• Progesterone counterbalances proliferative signals and may reduce the risk of malignant transformation of residual implants.
• Testosterone has a limited direct impact on endometriotic lesions; symptom improvement is typically mediated through body composition changes, mood/energy, and sexual function.

Integrative chiropractic role: Addressing lumbopelvic mechanics, scar tissue mobility, and pelvic floor coordination decreases pain and improves bowel/bladder function—frequently reducing analgesic use and enhancing tolerance to HRT when indicated.

Thyroid Optimization: Reverse T3, T4/T3 Combinations, and Desiccated Thyroid

Levothyroxine (T4) monotherapy is standard, yet some patients remain symptomatic despite normal TSH. Physiologically, the body converts T4 to T3 peripherally; stress, inflammation, illness, and caloric restriction increase deiodinase activity, favoring reverse T3 (rT3), which is inactive but receptor-competitive (Hoermann et al., 2019).

Clinical principles I use:

• Assess free T4, free T3, TSH, rT3, thyroid antibodies, iron status, vitamin D, B12, and selenium.
• If rT3 is high with low-normal free T3 and persistent symptoms, consider:
  • Reducing excessive T4 dosing that may be pushing rT3
  • Adding low-dose liothyronine (T3) in divided doses to improve tissue T3
  • Trialing desiccated thyroid extract (DTE) for patients who respond better to a T4/T3/T1/T2 matrix

Why this helps: T3 is the active hormone at the nuclear receptor; providing small physiologic amounts can restore signaling in patients with impaired conversion. DTE matches the multi-iodothyronine profile the body evolved with, which some patients perceive as more “physiologic,” though responses are individual (Hoang et al., 2013).

Gut-thyroid axis: Dysbiosis, SIBO, celiac spectrum, H. pylori, and food antigen load can impair absorption and conversion. I routinely pair thyroid adjustments with GI evaluation and interventions—elimination diets, targeted probiotics, bile flow support, and motility work. Thoracic and cervical mobility work, along with vagal maneuvers, complements this by improving autonomic inputs that influence motility and systemic inflammation.

Estriol, Estradiol, and Skin/Genitourinary Targets

Estriol (E3) is a weaker estrogen with preferential ER-? activity, often used for genitourinary syndrome of menopause (GSM) and dermatologic benefits. Topical estradiol (E2) is more potent systemically, but low-dose local preparations for vulvovaginal atrophy show minimal systemic absorption in most patients (Kingsberg et al., 2020).

Clinical reasoning:

• For GSM without systemic therapy, I begin with local estriol or ultra-low-dose estradiol and pelvic floor therapy.
• Skin goals often respond to estriol-inclusive topicals, collagen-supportive nutrition, and photoprotection.
• If vasomotor symptoms persist, systemic transdermal estradiol with micronized progesterone is considered, taking into account personal and family risk and oncology guidance, if relevant.

Practical Protocols and Rationale

• Iron repletion
  • Why: Restore mitochondrial function, myoglobin oxygen delivery, and neurotransmitter synthesis.
  • How: Oral bisglycinate or sucrosomial iron with vitamin C if tolerated; IV iron for malabsorption or urgency. Investigate bleeding and malabsorption concurrently.
• Progesterone personalization
  • Why: GABAergic modulation for sleep/anxiety, endometrial protection, mast cell stabilization.
  • How: Start with OMP 100–200 mg HS; if sedated or dysphoric, titrate dose or shift to sublingual troche fractions.
• Cortisol circadian repair
  • Why: Normalize metabolic flexibility, thyroid conversion, and sleep.
  • How: Morning light, protein-forward breakfast, breathwork, time-restricted eating, and graded movement; manual therapy to reduce nociceptive drive.
• Male fertility protection
  • Why: Maintain intratesticular testosterone and spermatogenesis.
  • How: Avoid exogenous T when actively conceiving; consider short-term clomiphene; optimize sleep, vitamin D, zinc, omega-3s, and resistance training.
• Post-oncology shared decisions
  • Why: Balance symptom relief with recurrence risk; honor autonomy.
  • How: Risk tools, multidisciplinary input, prioritization of nonhormonal options, meticulous documentation, phased trials if appropriate.
• Thyroid fine-tuning
  • Why: Resolve residual hypothyroid symptoms despite “normal” TSH.
  • How: Check rT3; adjust T4; add divided low-dose T3 or trial DTE; repair gut and sleep.
• Migraine/TIA hormone considerations
  • Why: Reduce cerebrovascular risk while controlling symptoms.
  • How: Prefer non-oral routes; address vascular risk factors; integrate headache-focused manual therapy and neuromuscular rehab.

How Integrative Chiropractic Care Fits Clinically

In my practice, integrative chiropractic care is a force multiplier:

• Autonomic balance: Spinal manipulation, soft-tissue work, and breathing mechanics reduce sympathetic excess, improving sleep and cortisol rhythm.
• Pain reduction: Less pain equals less inflammatory signaling and lower allostatic load, which improves hormonal resilience.
• Movement quality: Corrective exercise improves insulin sensitivity, mitochondrial function, and sex hormone balance.
• Pelvic mechanics: Lumbopelvic stability and pelvic floor coordination support endometriosis care, GSM, and IUD tolerance.
• Gut-brain axis: Thoracic mobility, rib mechanics, and vagal stimulation strategies support motility and reduce visceral hypersensitivity, aiding thyroid medication absorption and nutrient assimilation.

These integrated elements are detailed across my clinical publications and case discussions on my professional channels, where I routinely present outcomes from multimodal programs that pair precise endocrinology with targeted neuromusculoskeletal interventions.

• Clinical observations and resources:
  • Dr. Alexander Jimenez, DC, APRN, FNP-BC: chiropracticscientist.com
  • Professional updates and case insights: linkedin.com/in/dralexjimenez/

Key Takeaways

• Iron issues demand root-cause analysis; levonorgestrel IUDs can reduce heavy bleeding and anemia while minimizing systemic risk.
• Progesterone is highly individual; sublingual routes often salvage tolerability.
• Cortisol should be measured over a 24-hour rhythm; lifestyle and manual therapies can help restore the curve.
• In young men, lifestyle-first often restores testosterone; short SERM courses are tools, not crutches.
• DCIS is not an invasive cancer; receptor status guides, but does not dictate, absolute rules—use shared decision-making.
• Elevated creatinine needs context; inflammation and muscle mass matter.
• Non-oral estrogen is generally safer for vascular risk; match the route to the risk.
• Progesterone protects against endometriosis, even post-hysterectomy, when using estrogen.
• Thyroid optimization may require T3 or DTE with gut repair.
• Estriol shines for GSM and skin; systemic needs call for individualized estradiol-progesterone strategies.
• Integrative chiropractic care enhances endocrine outcomes by lowering nociception and autonomic strain, improving sleep, movement, and GI function.

References

• American College of Obstetricians and Gynecologists. (2010). Management of endometriosis
• Camaschella, C. (2015). Iron-deficiency anemia. New England Journal of Medicine
• Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., et al. (2016). U.S. medical eligibility criteria for contraceptive use. MMWR
• Dragoman, M. V., & Gaffield, M. E. (2016). The safety of levonorgestrel-releasing intrauterine devices. Contraception
• Gemmell, L. C., Webster, K. E., Kirtley, S., Vincent, K., Zondervan, K. T., & Missmer, S. A. (2017). The management of menopause in women with a history of endometriosis. Human Reproduction Update
• Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. (2013). Desiccated thyroid extract compared with levothyroxine. Journal of Clinical Endocrinology & Metabolism
• Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019). Homeostatic control of the thyroid axis. Frontiers in Endocrinology
• Kelly, D. M., & Jones, T. H. (2013). Testosterone and obesity. Frontiers in Hormone Research
• Kingsberg, S. A., Wysocki, S., Magnus, L., & Krychman, M. (2020). GSM in women: Treatment updates. Post Reproductive Health
• MacGregor, E. A. (2018). Migraine, menopause and hormone therapy. Post Reproductive Health
• Martínez-De La Cal, J., et al. (2023). Manual therapy effects on HRV: A review. Musculoskeletal Science and Practice
• Patel, A. S., Leong, J. Y., Ramos, L., & Ramasamy, R. (2019). Clomiphene citrate for male hypogonadism. Translational Andrology and Urology
• Prior, J. C., & Hitchcock, C. L. (2012). Progesterone for hot flushes: Randomized trial. Menopause
• Stalder, T., Kirschbaum, C., et al. (2016). Cortisol diurnal profiles. Psychoneuroendocrinology
• The North American Menopause Society. (2022). Hormone therapy position statement
• Thayer, J. F., & Lane, R. D. (2009). Claude Bernard and heart rate variability. Biological Psychology
• Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019). Risk of stroke and routes of menopausal hormone therapy. BMJ